Regeneron to get payments from French company

August

Eastview-based Regeneron Pharmaceuticals Inc., which is seeking to develop drugs for cancer, eye conditions and inflammatory conditions, said this morning it will receive at least $4.3 million a year for five years by allowing a French company to use its technology.

Sanofi-aventis SA will use Regeneronâ€™s proprietary VelociGene technology in its internal research programs, Regeneron said. The technology provides models of gene function and disease.

Regeneron lost $105.6 million on revenue of $125.02 million in fiscal 2007.

This entry was posted on Tuesday, August 5th, 2008 at 9:07 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: | Print Print | Email Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.

Business in the Burbs

Movers, shakers and newsmakers